Also, after administration of the T-cell depleting antibody directed against CD52, alemtuzumab (Campath), which is used to treat refractory leukemic CTCL (L-CTCL), skin T cells have been shown to secrete less IL-4 and more interferon gamma (IFNγ) than before the treatment [96]. This evidence concerns the gene IFNG and primary cutaneous T-cell non-Hodgkin lymphoma.